KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organon (OGN) Cash & Equivalents (2020 - 2025)

Organon has reported Cash & Equivalents over the past 6 years, most recently at $574.0 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $574.0 million for Q4 2025, down 14.96% from a year ago — trailing twelve months through Dec 2025 was $574.0 million (down 14.96% YoY), and the annual figure for FY2025 was $574.0 million, down 14.96%.
  • Cash & Equivalents for Q4 2025 was $574.0 million at Organon, down from $672.0 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for OGN hit a ceiling of $1.0 billion in Q3 2021 and a floor of $141.0 million in Q1 2021.
  • Median Cash & Equivalents over the past 5 years was $635.5 million (2025), compared with a mean of $603.0 million.
  • Biggest five-year swings in Cash & Equivalents: surged 6041.67% in 2021 and later plummeted 50.5% in 2022.
  • Organon's Cash & Equivalents stood at $737.0 million in 2021, then fell by 4.21% to $706.0 million in 2022, then dropped by 1.84% to $693.0 million in 2023, then decreased by 2.6% to $675.0 million in 2024, then fell by 14.96% to $574.0 million in 2025.
  • The last three reported values for Cash & Equivalents were $574.0 million (Q4 2025), $672.0 million (Q3 2025), and $599.0 million (Q2 2025) per Business Quant data.